We were disheartened to learn earlier this week that the results from the Catabasis Phase 3 trial for edasalonexent (PolarisDMD) did not meet its primary or secondary endpoints.

On October 27, 2020, PPMD was joined by Joanne M. Donovan, MD, PhD, Chief Medical Officer of Catabasis Pharmaceuticals for a webinar to discuss the trial and results in more detail, as well as the company’s plans for the edasalonexent program going forward.

If you missed the live event, the recording can be found below.

Watch the Recording

Survey: Understanding Your Experience with Clinical Trial Terminations

Clinical trial terminations can be a devastating experience for any family participating in a trial. In the hope of improving the process for future trials, PPMD and Duchenne UK are working together on a survey to learn more about the patient and family experience around clinical trials that have stopped or were terminated.

If you or your child has taken part in this trial, or in any Duchenne clinical trial that has been terminated, please help us by completing our survey.

Take Survey >

Please note if you have participated in more than one trial that was terminated, you can take the survey a second time after you complete the first survey.